Transforming medicine and changing lives

AskNews

April 29, 2021

Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program

Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta. Selecta to postpone IND submission until at least the fourth quarter of 2021. Empty capsid (SEL-399) study remains on track ...read the news

We are on a never-ending quest to advance genetic technology

and life-saving AAV gene therapy

In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is leading the way.

Learn about AskBio »

gene therapy

Revolutionizing gene therapy

Cures for life-altering diseases depend on new technology to lower the cost of treatment and increase supply for every patient who needs it.

Explore our technology »

Clinical Pipeline

Changing lives

Our clinical pipeline is the direct result of listening to patients, their families, their care teams and disease-advocacy organizations.

Discover our pipeline »

Putting patient care first

The voices of patients drive everything we do. They propel our research and the urgent need to find cures.

For Patients »

Work with us

Advancing research

Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.

Building careers

Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.

Events

Gene Therapy Europe 2021

May 5

May 6

Join us at Gene Therapy Europe, an online congress from May 5-6, 2021 that will feature in-depth discussions on advanced analytical strategies and next-gen technologies to progress gene therapy development from discovery to clinical stages.

News